“New Ozempic (semaglutide) 0.25 mg and 0.5 mg pre-filled pen presentation”
04 Jun 2025
Both the new 3 mL and existing 1.5 mL pens deliver the same dose of semaglutide, contain the same number of doses, and use the same administration and dosing instructions. The main difference is that the 3 mL pen holds a larger volume per dose. Both presentations are bioequivalent and considered interchangeable for delivering 0.25 mg or 0.5 mg per dose.
For patients:
-
Check with your pharmacy to ensure they have your required Ozempic presentation before your next dose.
-
During the transition, limited quantities of the 1.5 mL pens may still be available until stocks run out.
-
If your prescription is for the 1.5 mL pen and your pharmacy only has the 3 mL pen, you may need a new PBS prescription until the two presentations are “a-flagged” (expected from 1 July 2025).
-
For private (non-PBS) prescriptions, pharmacists can supply either the 1.5 mL or 3 mL pen without a new prescription.
-
Always double-check the pen strength before use, especially for patients switching between 0.25/0.5 mg and 1 mg pens.
For prescribers:
-
The 1.5 mL presentation is now listed as Supply Only on the PBS and will be discontinued on 1 December 2025.
-
From 1 June 2025, PBS prescriptions can only be written for the new 3 mL pen.
-
Until a-flagging is implemented, existing 1.5 mL PBS prescriptions cannot be used to access the 3 mL pen.
For pharmacists:
-
The new 3 mL pens are available on the PBS (criteria apply).
-
1.5 mL pens remain available only for prescriptions written before 1 June 2025.
-
Ensure patients receive the correct strength, especially with multiple 3 mL presentations of Ozempic available.
Patients and healthcare providers are encouraged to review the Ozempic Product Information (PI) and Consumer Medicines Information (CMI) for detailed guidance on administration and dosing.
Important: The Ozempic 0.25 mg/0.5 mg supply remains limited throughout 2025. Patients should contact their pharmacy or doctor if they cannot obtain their medicine.
For more information: About the Ozempic (semaglutide) shortage
